Top Tweets for #ESG401

over 1 year ago

🇨🇳 #Escugen announced that the results of its TROP2-targeting #ADC, #ESG401, for the treatment of brain metastases in patients with advanced HER2-negative breast cancer have been published online in ESMO Open. https://t.co/JYPRuLDdX7 ESG401 is a further optimized ADC comprising a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to SN-38, a topoisomerase I inhibitor, via a proprietary novel stable linker. In the brain metastasis subgroup, 17 patients who completed at least one post-treatment efficacy evaluation were included in the analysis, with a median follow-up of 23.9 months. the intracranial ORR was 41% (7/17), including 3 patients who achieved intracranial CR. The intracranial DCR was 76% (13/17). The overall ORR was 53% (9/17), and the overall DCR was 71% (12/17), with a median PFS of 5.7 months.

chuminhua432's tweet photo. 🇨🇳 #Escugen announced that the results of its TROP2-targeting #ADC, #ESG401, for the treatment of brain metastases in patients with advanced HER2-negative breast cancer have been published online in ESMO Open. https://t.co/JYPRuLDdX7

ESG401 is a further optimized ADC comprising a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to SN-38, a topoisomerase I inhibitor, via a proprietary novel stable linker.

In the brain metastasis subgroup, 17 patients who completed at least one post-treatment efficacy evaluation were included in the analysis, with a median follow-up of 23.9 months.

the intracranial ORR was 41% (7/17), including 3 patients who achieved intracranial CR. The intracranial DCR was 76% (13/17). The overall ORR was 53% (9/17), and the overall DCR was 71% (12/17), with a median PFS of 5.7 months.

743

Top Tweets for #ESG401

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users